Table 2.
Clinical trials of peptide vaccines for HNSCC patients (clinicaltrials.gov)
| Treatment | Study phase | Trial status | ClinicalTrials.gov identifier | Sponsor |
|---|---|---|---|---|
| Mutant p53 peptide pulsed dendritic cell vaccine | Phase 1 | Completed | NCT00404339 | Robert Ferris |
| HPV therapeutic vaccine: PepCan (HPV-16 E6 peptides) | Phase 1 | Recruiting | NCT03821272 | University of Arkansas |
| Phase 2 | ||||
| Peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab | Phase 1 | Not yet recruiting | NCT04266730 | UNC Lineberger Comprehensive Cancer Center |
| Peptide vaccine consisting of arginase-1 (ARG1) peptides and Montanide ISA-51 | Phase 1 | Recruiting | NCT03689192 | Herlev Hospital |
| CNGRC peptide-TNF alpha conjugate | Phase 1 | Completed | NCT00098943 | European Organisation for Research and Treatment of Cancer: EORTC |
| A amino acid peptide from indoleamine 2,3-dioxygenase | Phase 2 | Recruiting | NCT04445064 | Cliniques universitaires Saint-Luc-Université Catholique de Louvain |
| Combination of UCPVax vaccine and atezolizumab | Phase 2 | Recruiting | NCT03946358 | Centre Hospitalier Universitaire de Besancon |
| Human papillomavirus 16 E7 peptide | Phase 1 | Completed | NCT00019110 | National Cancer Institute (NCI) |
| S-488210/S-488211 (freeze-dried injectable formulation containing peptides) | Phase 1 | Recruiting | NCT04316689 | Shionogi |
| Ras peptide cancer vaccine containing DetoxPC adjuvant, interleukin-2 (IL-2), sargramostim (GM-CSF) | Phase 2 | Completed | NCT00019331 | National Cancer Institute (NCI) |
| Trojan peptides MAGE-A3 and HPV 16 | Phase 1 | Completed | NCT00257738 | University of Maryland, Baltimore |
| P16_37-63 peptide combined with Montanide® ISA-51 VG | Phase 1 | Completed | NCT02526316 | Oryx GmbH & Co. KG |
| Combination of pembrolizumab, HPV-16 E6/E7 and cisplatin-based chemoradiotherapy | Phase 2 | Recruiting | NCT04369937 | Robert Ferris |
| Personalized adjuvanted vaccine, GEN-009 | Phase 1 | Active, not recruiting | NCT03633110 | Genocea Biosciences, Inc |
| Phase 2 |
HPV human papillomavirus, MAGE melanoma antigen E, TNF tumor necrosis factor